Articles

Find an Article

Filter articles

Applied Filters

Showing 71 to 80 of 272 results

LSIPR 50 2017: Paul Nurse

UK10-11-2017

Paul Nurse was selected in the LSIPR 50 2017 publication for his influence on the life sciences industry. He featured in the business and innovation section, as LSIPR reports.

LSIPR 50 2017: Michael Salzmann

Switzerland10-11-2017

Michael Salzmann was selected in the LSIPR 50 2017 publication for his influence on the life sciences industry. He featured in the business and innovation section, as LSIPR reports.

LSIPR 50 2017: Marcus Dalton

EU10-11-2017

Marcus Dalton was selected in the LSIPR 50 2017 publication for​ ​his influence on the life sciences industry. He featured in the legal section, as LSIPR reports.

LSIPR 50 2017: Galit Gonen

UK10-11-2017

Galit Gonen was selected in the LSIPR 50 2017 publication for​ ​her influence on the life sciences industry. She featured in the legal section, as LSIPR reports.

LSIPR 50 2017: Mr Justice Richard Arnold

UK10-11-2017

Mr Justice Richard Arnold was selected in the LSIPR 50 2017 publication for​ ​his influence on the life sciences industry. He featured in the legal section, as LSIPR reports.

LSIPR 50 2017: Jörg Thomaier

Germany10-11-2017

Jörg Thomaier was selected in the LSIPR 50 2017 publication for​ ​his influence on the life sciences industry. He featured in the legal section, as LSIPR reports.

Case report: diagnostics in Germany

Germany09-11-2017Joachim Wachenfeld

In September 2016, the German Federal Supreme Court decided a patent case that could have a major impact on companies working in the diagnostics field. Joachim Wachenfeld of Vossius & Partner reports.

Raising the plausibility bar

EU26-10-2017David Carling and Richard Wells

Patent applicants have long wrestled with the question of how much experimental evidence to include in a new patent application. David Carling and Richard Wells of Potter Clarkson examine the issue in Europe.

Plausibility: How much information is enough?

EU24-10-2017Iain Armstrong

Patentees should ensure their applications meet the plausibility standard right from the start, says Iain Armstrong of HGF, who investigates one of the developing challenges facing patentability in the life sciences field.

After Brexit: new directions for clinical trials

UK10-10-2017Rachel Bradley

If the UK government changes the rules for clinical trials after Brexit, the regimes in the UK and the EU will diverge and possibly make trials more complex and costly, as Rachel Bradley of Penningtons Manches reports.

Showing 71 to 80 of 272 results

LSIPR